Johns Hopkins HIV Guide
Didanosine
INDICATIONS
FDA
FDA
- Treatment of HIV infection in combination with other antiretrovirals.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 16, 2023
Citation
Auwaerter, Paul G, and Janessa Smith. "Didanosine." Johns Hopkins HIV Guide, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine.
Auwaerter PG, Smith J. Didanosine. Johns Hopkins HIV Guide. 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine. Accessed September 22, 2023.
Auwaerter, P. G., & Smith, J. (2023). Didanosine. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine
Auwaerter PG, Smith J. Didanosine [Internet]. In: Johns Hopkins HIV Guide. ; 2023. [cited 2023 September 22]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Didanosine
ID - 545057
A1 - Auwaerter,Paul,M.D.
AU - Smith,Janessa,Pharm.D. BCPS
Y1 - 2023/07/16/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
